Malaria Diagnostics Market Size, Share & Trends Analysis Report By Technology (Microscopy, Rapid Diagnostic Tests, Molecular Diagnostic), By End-use (Clinics, Hospitals, Diagnostic Centers), By Region, And Segment Forecasts, 2023 - 2030

Malaria Diagnostics Market Size & Trends

The global malaria diagnostics market size was valued at USD 786.51 million in 2022 and is estimated to grow at a compound annual growth rate (CAGR) of 4.73% from 2023 to 2030. The rising demand for malaria diagnostics and the introduction of novel diagnostic techniques are the key factors driving the market. Malaria is one of the most widespread life-threatening diseases, commonly occurring in tropical and subtropical regions due to changing climate, low economic growth, underdeveloped healthcare infrastructure, and lack of access to advanced treatment. The tropical disease caused by the female Anopheles mosquito, infected by the Plasmodium species caused over 4,35,000 deaths globally in 2017, as stated by the World Health Organization (WHO). Statistics from the same source indicate that over 219 million cases of malaria were recorded globally, with over 92% of cases being reported from Africa, 6% from South East Asia, and 2% from the Eastern Mediterranean regions.

In Africa, non-governmental and governmental organizations announced initiatives to support the COVID-19 research and control program. The Global Fund to Fight AIDS, Tuberculosis, and Malaria permitted receivers to use funds from already existing grants in order to control COVID-19. Efforts were taken to minimize and control the spread of the COVID-19 virus, to avoid situations that arised during the Ebola outbreak, where millions of Malaria cases were left untreated due to the severity of the Ebola virus. These were some of the driving market factors during the COVID-19 pandemic.

For instance, in May 2023,the Global Health Innovative Technology (GHIT) Fund received a commitment of USD 24 million over three years from the Bill & Melinda Gates Foundation. This funding is allocated for GHIT Fund's third five-year plan, spanning from FY2023 to FY2027. The GHIT Fund has been actively investing in the development of new products and undertaking portfolio management initiatives to address global health challenges. Their efforts are focused on supporting Japanese technology and innovation to combat infectious diseases, including malaria, tuberculosis, and neglected tropical diseases (NTDs), which disproportionately impact vulnerable and underserved populations worldwide.

It is one of the leading causes of death in many African, Asian, and Latin American countries, such as Uganda, the Democratic Republic of Congo, Columbia, Peru, and India. Malaria during pregnancy can cause low birth weights, stillbirths, and congenital infections. Technological advancements are also expected to be one of the key drivers for the market for malaria diagnostics. Increasing demand and rising need for high-quality and cost-efficient diagnostic methods are likely to trigger advancements that can offer improved access to diagnostics, especially in remote areas. Heavy investments by government bodies and private investors to curb the disease prevalence is also one of the major factors driving the market for malaria diagnostics. According to the data published by WHO, in 2017, approximately USD 3.1 billion were invested in the control and elimination of the disease by private international investors and government authorities of endemic nations. Over 312 million rapid diagnostic tests were delivered globally, mostly in the WHO African region, which is the worst affected region.

Technology Insights

The Rapid Diagnostic Tests (RDTs) segment dominated the market and accounted for a revenue share of 53.69% in 2022. Microscopy was the second-largest segment owing to intermittent usage of the technique for disease diagnosis. It is one of the traditional and most reliable methods for the diagnosis of disease. According to the estimates from WHO, over 204 million microscopic malarial tests were conducted globally. Malarial parasites including P. falciparum, P. malariae, P. ovale, and P. vivax, at different stages of life, can be identified through this method. Additionally, the parasite density can also be quantified to accordingly design treatment plans. The molecular diagnostic test segment is expected to witness the fastest growth over the forecast period due to the accurate diagnosis offered by these tests.

Molecular diagnostic tests include conventional polymerase chain reaction (PCR) and quantitative or Real Time-PCR (qPCR). The usage of qPCR using DNA extracted from blood samples has been used to detect low parasite counts or mixed infections. These tests are accurate, highly sensitive, and capable of detecting low parasite count. However, the market share of these tests is less owing to high costs, as well as a lack of specialized laboratories and a skilled workforce. An RDT is another method used for detecting specific malaria antigens in the blood sample. Estimates from WHO indicate that over 312 million RDTs were delivered globally in the year 2016. According to National malaria control program reports and sales data from manufacturers, 225 million P. falciparum tests were delivered in Africa, while the remaining were combination tests for P. falciparum, P. malariae, P. ovale, and P. vivax.

End-use Insights

The clinics segment held the largest share of 42.06% of the malaria diagnostics market in 2022. Increasing focus on the use of RDTs for quick turnaround time, affordability, and ease of access is one of the key factors responsible for the dominance. Early diagnosis and treatment are crucial for malaria management and reducing complications. Compared to hospitals, clinics often have fewer patients, which enables them to promptly administer suitable antimalarial medications, ultimately leading to improved patient outcomes.

The diagnostics centers segment is estimated to grow at a fastest CAGR over the forecast years. Rising awareness amongst target population has shifted focus on diagnosing the disease from healthcare providers with specialized expertise. Enhanced testing capacity, well equipped laboratories, and assurance of accurate quality control process and results are some of the other factors responsible for segment growth in the foreseeable future. Additionally, rise in government initiatives aimed at providing services such as reimbursement is another major factor anticipated to drive the market.

Regional Insights

Africa is expected to lead the market owing to the highest disease burden. The African region had the highest revenue share of 88.17% in 2022. P. falciparum is the most prevalent malarial parasite in the region, accounting for an estimated 99% of all cases in Africa. According to the WHO, an estimated 92.0% of global malaria cases and 93% of global malarial deaths were recorded in this region. These facts are indicative of the rising prevalence of malaria in Africa.

In Southeast Asia, the market is estimated to hold the second position with India accounting for the largest share of the regional market. The Southeast Asian region is expected to grow at a CAGR of 5.0%. The disease diagnostic testing, in terms of volume, in India is majorly led by microscopy testing. With the rising awareness about the disease and increasing funding from the private sector, the need for diagnostic testing and care-based surveillance systems is anticipated to increase, thereby propelling the market growth.

Key Companies & Market Share Insights

Abbott; bioMérieux; Beckman Coulter Inc.; Siemens Healthineers; Leica Microsystems GmbH; and Bio-Rad Laboratories, Inc., in particular, account for significant market shares due to their strong global presence and distribution channel. For instance, bioMérieux has a vast network of distributors in more than 150 countries through 42 subsidiaries providing diagnostic solutions. Some of the prominent players in the malaria diagnostics market include:

• Access Bio., Inc.

• Abbott Laboratories

• Premier Medical Corporation Pvt. Ltd.

• Sysmex Partec GmbH

• bioMérieux

• Beckman Coulter, Inc.

• Siemens Healthineers

• Leica Microsystems GmbH

• Nikon Corporation

• Olympus Corporation

• Bio-Rad Laboratories, Inc.

Malaria Diagnostics Market Report Scope

Global Malaria Diagnostics Market Report Segmentation

This report forecasts revenue and volume growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global malaria diagnostics market report on the basis of technology, end-use, and region:

• Technology Outlook (Revenue, USD Million, 2018 - 2030)

  • Microscopy

  • Rapid Diagnostic Tests (RDTs)

  • Molecular Diagnostic Tests

    • Conventional PCR

    • Real-Time PCR (qPCR)

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Clinics

  • Hospitals

  • Diagnostic Centers

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • Africa

    • Nigeria

    • Democratic Republic of Congo

    • Uganda

  • Southeast Asia

    • India

    • Myanmar

    • Indonesia

  • Eastern Mediterranean

    • Saudi Arabia

    • Pakistan

  • Western Pacific

    • China

    • Papua New Guinea

    • Cambodia

  • Americas

    • Venezuela

    • Brazil

    • Colombia

  • Europe

    • Turkey

    • France

    • U.K.

    • Germany